Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*
GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
GSK boosts the geographic scope of the dolutegravir (Tivicay®) licence beyond the stated territory by more than 30 middle-income countries.